Company Search:
Advanced Search
Sponsored Links
Grifols SA - ADR Company Snapshot
Grifols SA operates in the Biological products exc. diagnostic sector. In addition to historical fundamental analyses, the complete report available to purchase compares Grifols SA with three other pharmaceutical manufacturers in North America: Eisai Company Limited (2018 sales of $5.42 billion of which 49% was Pharmaceutical Business -Japan), Zoetis Inc ($5.83 billion of which 50% was International), and Perrigo Company PLC ($4.73 billion of which 51% was CSCA).

Sales Analysis. Grifols SA reported sales of $5.29 billion for the year ending December of 2018. This represents an increase of 7.5% versus 2017, when the company's sales were $4.92 billion. This was the third consecutive year of growth at Grifols SA. Sales of Bio Supplies saw an increase that was more than double the company's growth rate: sales were up 158.6% in 2018, from $76.08 million to $196.77 million. Grifols SA also saw significant increases in sales in Hospital (up 23.4% to $140.75 million) and Others/raw Materials (up 27.2% to $26.45 million) .
  Stock Performance Chart for Grifols SA - ADR
  Stock Data: Recent Stock Performance:
  Current Price (2/14/2020): 24.64
(Figures in U.S. Dollars)
1 Week 5.9%   13 Weeks 4.2%  
4 Weeks 13.6%   52 Weeks 24.4%  
Grifols SA - ADR Key Data:
  Ticker: GRFS Country: United States
  Exchanges: NAS Major Industry: Pharmaceuticals & Biotechnology
    Sub Industry: Biological Products Exc. Diagnostic
  2018 Sales 5,286,527,420
(Year Ending Jan 2019).
Employees: 21,243
  Currency: U.S. Dollars Market Cap: 16,857,094,901
  Fiscal Yr Ends: December Shares Outstanding: 684,135,345
  Share Type: ORDINARY Closely Held Shares: 145,690,603
Feedback | Terms and Conditions | Privacy Policy | Site Index
CorporateInformation® website and selected data Copyright © 2000 - by The Winthrop Corporation. All Rights Reserved. Except for quotations by established news media, no pages on this site may be reproduced, stored in a retrieval system, or transmitted for commercial purposes, in any form or by any means, electronic, mechanical, photocopying, recording, or otherwise without prior written permission. Information is believed reliable, but accuracy, completeness and opinions are not guaranteed.